Forward Pharma A/S American Depositary Shares Quote & Summary Data
Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don’t know the stock symbol? Use the Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.
“Best Ask” is the lowest price currently being asked for a block of stock.
“52 Week Low” is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period.
Prices during the When Issued trading period are used in the 52 week high/low calculation.
Company Description (as filed with the SEC)
Forward Pharma A/S is a Danish biopharmaceutical company that until recently was actively developing FP187, a proprietary formulation of DMF, for the treatment of several inflammatory and neurological indications, including MS. DMF is an immunomodulator that can be used as a therapeutic to improve the health of patients with immune disorders, including MS. On February 1, 2017, our License Agreement with Biogen became effective. Pursuant to the License Agreement, Biogen paid us a non-refundable cash fee of $1.25 billion. The License Agreement provides Biogen with a co-exclusive license in the U.S. (which will be converted into an exclusive license if certain conditions are met within the time period set forth in the License Agreement), and an exclusive license outside the U.S., to the Company’s intellectual property. For more, see “–B. Business Overview–Our Company–Settlement and License Agreement. . More .
Where does FWP fit in the risk graph?